Anaptysbio (ANAB) Capital Expenditures Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Capital Expenditures Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 22,433.30% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -73.62% |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | -34.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -34.29% |
| Dec 31, 2025 | -99.62% |
| Sep 30, 2025 | -65.71% |
| Jun 30, 2025 | 18.18% |
| Mar 31, 2025 | 29.63% |
| Dec 31, 2024 | -6.07% |
| Sep 30, 2024 | -78.40% |
| Jun 30, 2024 | -82.63% |
| Mar 31, 2024 | -84.57% |
| Dec 31, 2023 | 60.00% |
| Sep 30, 2023 | 224.00% |
| Jun 30, 2023 | 143.59% |
| Mar 31, 2023 | 218.18% |
| Dec 31, 2022 | 1,150.00% |
| Sep 30, 2022 | -70.93% |
| Jun 30, 2022 | -90.96% |
| Mar 31, 2022 | -82.65% |
| Dec 31, 2021 | -95.50% |
| Sep 30, 2021 | 95.45% |
| Jun 30, 2021 | 939.76% |